TC
XBI icon

Tavio Capital’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Tavio Capital’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-115,821
Closed -$10M – 13
2017
Q3 		$10M Buy
+115,821
New +$9.29M 4.08% 8

Other funds holding XBI

Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Tavio Capital's XBI Position: Q4 2017 in Review

Tavio Capital sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2017, closing a stake of 115,821 shares — an estimated $10M sold.

Tavio Capital first reported a position in XBI in Q3 2017 and held it in 1 quarter. The position peaked at $10M in Q3 2017. 397 funds tracked by Wall St. Rank hold XBI as of Q4 2017.

  • Tavio Capital reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2017 after selling out during the quarter.
  • Tavio Capital sold 115,821 State Street SPDR S&P Biotech ETF shares in Q4 2017, an estimated $10M.
  • Tavio Capital first reported a position in State Street SPDR S&P Biotech ETF in Q3 2017 and held it in 1 quarter.
  • Tavio Capital's State Street SPDR S&P Biotech ETF position peaked at $10M in Q3 2017.
  • 397 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2017.

Based on Tavio Capital's 13F filing for Q4 2017, filed 12 Feb 2018.